Paradigm Biopharmaceuticals . Share Price and Company Fundamentals



Price
$2.22
Change
0.000 (0.000%)
52 week
1.87 - 3.19

Last traded: Yesterday at 6:10 AM

Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.

Key Metrics

PE ratio

-

PB ratio

5.69

Dividend yield

Beta

1.56

Market cap

$509.73M

Enterprise value

$423.65M

Company profile

Primary activitiesBiopharmaceutical company focused on repurposing the drug, pentosan polysulphate sodium, for the lead clinical indication of bone marrow edema
Industry / SectorBiotechnology / Healthcare
Websitehttp://www.paradigmbiopharma.com
Mailing address500 Collins Street Level 15 Melbourne VIC 3000 Australia
Phone / Fax /
Share registryCOMPUTERSHARE INVESTOR SERVICES PTY LIMITED

Dividends

Paradigm Biopharmaceuticals . does not pay dividends.

Company Executives

As of Jul 2021, following are the company executives and directors listed on Paradigm Biopharmaceuticals ..

NameTitleAgeTotal Pay
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTCCEO, MD & Exec. Chairman61632.36k
Mr. Justin CahillChief Financial Officer
Dr. Jeannette JoughinChief Operating Officer
Dr. Ravi KrishnanChief Scientific Officer
Ms. Simon WhiteDirector of Investor Relations
Dr. Michael ImperialeGlobal Head of Safety
Dr. Donna L. SkerrettChief Medical Officer & Exec. Director63
Ms. Beverley HuttmannCommercial Head
Ms. Michelle CoffeyGlobal Head of Regulatory Affairs
Mr. Kevin G. HollingsworthCompany Sec.67

Profitability and management effectiveness

Profit margin

0.00%

Operating margin

-940.53%

Return on assets

-20.49%

Return on equity

-33.10%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Paradigm Biopharmaceuticals . is 509.73M and its enterprise value is 423.65M. The enterprise value to revenue ratio of PAR is 137.71.

The PAR's stocks Beta value is 1.56 making it 56% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Paradigm Biopharmaceuticals . (PAR)

Paradigm Biopharmaceuticals . (ASX:PAR) Frequently Asked Questions

1. What is Paradigm Biopharmaceuticals .'s Stock Symbol?

Paradigm Biopharmaceuticals . trades on ASX under the ticker symbol "PAR".

2. What is Paradigm Biopharmaceuticals .'s stock price today?

One share of PAR stock can currently be purchased for approximately $2.22.

3. How can I contact Paradigm Biopharmaceuticals .?

Paradigm Biopharmaceuticals .'s mailing address is 500 Collins Street Level 15 Melbourne VIC 3000 Australia. The company can be reached via phone at .

4. What is Paradigm Biopharmaceuticals .'s official website?

The official website of Paradigm Biopharmaceuticals . is http://www.paradigmbiopharma.com.

5. Which share registry manages Paradigm Biopharmaceuticals .'s stock?

Paradigm Biopharmaceuticals .'s stock is managed by COMPUTERSHARE INVESTOR SERVICES PTY LIMITED.